

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/767,352	
			Filing Date	01/30/2004	
			First Named Inventor	Barry Maurer	
			Group Art Unit	1618	
Examiner Name	Blessing M. Fubara				
Sheet	C1	of	C1	Attorney Docket Number	9022-41

U.S. PATENTS AND PATENT PUBLICATIONS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	1.	US-5,891,466		Yesair	04/06/1999

U.S. PATENT APPLICATIONS				
Examiner Initials*	Cite No.	U.S. Serial No.	Name of Applicant of Cited Document	Date of Filing of Cited Document MM-DD-YYYY

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			
	2.	WO	03/031593	A2	Yesair et al.	04/17/2003	

OTHER NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
	3.	Lepage et al. "Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis", <i>The Journal of Pediatrics</i> 141(2):178-185 (2002)			
	4.	Supplementary European Search Report corresponding to European Patent Application No. 04706566.9 dated April 22, 2010.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.